Evidence map›Paper›PMID 41572106›Full record

ReviewPharmaceutical research2026

Lipid Nanoparticle Development in Practice: Challenges and Collective Insights.

Xiuling Lu, Sheyda Ranjbar, Fan Zhang, Yahya Choonara, Ryan M Pearson, John Fetse, Rui He, Esraa Mohamed, Amalendu Ranjan, Muhammad Delwar Hussain and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Versatile Applications of Antisense Oligonucleotides in Modern Medicine.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiuling LuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA. xiuling.lu@uconn.edu.ORCID http://orcid.org/0000-0002-1961-8156
Sheyda RanjbarDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.
Fan ZhangDepartment of Pharmaceutical Sciences, University of Florida School of Pharmacy, Gainesville, FL, 32610, USA.
Yahya ChoonaraFaculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa.
Ryan M PearsonDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.
John FetseDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Binghamton, Binghamton, NY, 13790, USA.
Rui HeDepartment of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, IA, 52246, USA.
Esraa MohamedDepartment of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, IA, 52246, USA.
Amalendu RanjanDepartment of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX, 76107, USA.
Muhammad Delwar HussainDepartment of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD, 21853, USA.
Ashraf Hatim Osman Mohamed KheirDepartment of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD, 21853, USA.
Chun-Wan YenGenentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, IA, 52246, USA. aliasger-salem@uiowa.edu.
Mitra MosharrafHTD Biosystems Inc., 3197 Independence Drive, Livermore, CA, 94551, USA. mitra.mosharraf@htdcorp.com.

Funding

Together: Transforming and Translating Discovery to Improve HealthKL2TR001429 · NCATS · UNIVERSITY OF FLORIDA · PI GUIRGIS, FAHEEM W, LEEUWENBURGH, CHRISTIAAN · 2015 to 2023
$5.5M
NCATS NIH HHS KL2 TR001429
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have emerged as a versatile delivery platform for improving pharmacokinetic performance, protecting nucleic acid cargo, and enabling tissue- and cell-specific targeting. Continued advancement of LNP-based therapeutics requires a deeper understanding of how raw material quality, formulation parameters, nanoparticle architecture, and biological context collectively influence clinical performance. In this Perspective, we discuss key challenges, practical insights, and lessons learned from ongoing LNP development efforts, with emphasis on characterization strategies, delivery specificity, scale-up considerations, long-term stability, and emerging applications of artificial intelligence. We highlight the importance of rational design principles, robust and reproducible manufacturing practices, comprehensive analytical characterization, and innovative approaches to support the next generation of LNP technologies.

Indexed as

Drug CarriersLipidsNanoparticlesAnimalsArtificial IntelligenceDrug Delivery SystemsHumansDrug CarriersLipidscharacterizationdrug deliverylipid nanoparticlescale upstability

Identifiers

PMID41572106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.